Outset Medical, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Outset Medical, Inc. (OM)

If you purchased or otherwise acquired Outset Medical securities between August 2025 and November 10, 2025, you may be eligible to join this securities investigation and seek compensation.

About Outset Medical

Outset Medical is a medical-technology company that designs and manufactures dialysis systems for use in both clinical and home settings. Its primary product, the Tablo Hemodialysis System, is marketed as a simplified and cost-effective solution for patients and providers.

Potential Concerns Under Investigation

Attorneys are reviewing whether Outset Medical and certain executives made false or misleading statements or failed to disclose material information about the company’s financial condition, demand trends, and sales outlook between August 2025 and November 10, 2025.

On August 6, 2025, Outset Medical issued second-quarter results, emphasizing “continued momentum” and “excellent progress on our path to achieve near-term profitability,” and raised full-year revenue guidance to $122 million to $126 million, expressing confidence in the company’s sales pipeline and market demand.

Lawyers are examining whether these public statements accurately reflected internal data and demand conditions. Reports indicate that, at the time, the company was already experiencing slower-than-expected hospital orders and delays in large customer purchases.

On November 10, 2025, after markets closed, Outset Medical released its third-quarter 2025 results, reporting revenue of $29.4 million, up just 3% year over year, and cut full-year guidance to $115 million to $120 million. Management attributed the lower guidance to order timing and the delay of several large sales into late 2025 and early 2026.

Following these announcements, Outset Medical’s stock fell approximately 47%, dropping from $12.07 at the close on November 10 to $6.22 on November 11, 2025, causing significant harm to investors.

Lawyers are investigating whether Outset Medical’s prior statements about its financial outlook, sales pipeline, and anticipated cash use adequately reflected known challenges, including delayed customer orders and budget constraints across hospital systems.

Your Rights and Next Steps

This is an ongoing investigation and not a filed lawsuit. Investors who purchased or otherwise acquired Outset Medical securities between August 2025 and November 10, 2025, and suffered losses may have legal rights. If evidence shows that investors were misled, the case could lead to a class-action lawsuit to recover damages for affected shareholders.

Lawyers are available to help investors review their options and determine whether they qualify to participate. There is no cost or obligation to join the investigation, and participation is confidential.

You May Be Entitled to Compensation

Securities investigations are time-sensitive, and acting promptly can help preserve your rights. If you purchased or otherwise acquired Outset Medical (OM) securities during the relevant period, you may be eligible to seek compensation for your losses.

To learn more and join the investigation, complete the form below.